Orally active, ATP site-targeting, potent and selective protein kinase C (PKC) inhibitor with in vivo immunosuppressive efficacy.
Sotrastaurin (AEB071) is an orally active, ATP site-targeting, potent and selective protein kinase C (PKC) inhibitor (Ki in nM/isoform = 0.95/α, 0.64/βI, 2.1/δ, 3.2/ε, 1.8/η and 2.2/θ; IC50 = 2.1/α, 2.0/βI, 1.3/δ, 6.2/ε, 6.1/η and 1.0/θ with 10 μM ATP). Sotrastaurin inhibits TCR/CD28-mediated T cell activation in cultures (IC50 = 54 nM by Jurkat IL-2 promoter reporter line) and exhibits in vivo immunosuppressive efficacy in rat models of local graft versus host (GvH) reaction and cardiac transplantation (10 and 30 mg/kg p.o. q.d. or b.i.d.).